Cancer Tissue Diagnostics Market Growing at CAGR — 2026 Report

Cancer Tissue Diagnostics by Application (Hospitals, Clinics, Others), by Types (Immunohistochemistry (IHC) Test, In Situ Hybridisation Test), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $5500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $5500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Cancer Tissue Diagnostics Market Size | CAGR 7.2 Forecast 2033

Cancer Tissue Diagnostics Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $5500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $5500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cancer Tissue Diagnostics Market Overview

Cancer tissue diagnostics encompass the laboratory profiling of solid-tumor biopsies to guide therapy selection and monitor disease progression, making them the backbone of precision oncology. The Cancer Tissue Diagnostics market size is valued at USD 14.7 billion in 2025 and is projected to reach USD 29.4 billion by 2033, translating to a robust 9.1% CAGR over the forecast period. This growth outlook is anchored in the expanding global cancer burden, accelerating adoption of companion diagnostics, and continuous shifts toward value-based cancer care.

Loading chart…

Macro drivers fuelling market forecast optimism include increasing reimbursement for molecular tests, a surge in multiplexed assays, and biopharma’s heavy R&D spend on targeted therapeutics. Key forces reshaping the competitive landscape are the pivot from manual IHC to fully automated staining platforms, tightening laboratory-developed-test (LDT) regulations in the U.S. and EU, and a supply-chain shift toward on-shore reagent manufacturing. North America captured 42% of 2025 global revenue—driven by high testing volumes and favorable reimbursement—while Asia-Pacific is the fastest-growing region, underpinned by expanding pathology networks in China and India and accelerating adoption of precision-oncology guidelines.

Report Overview

Report Attribute	Details
Market size value in 2025	5.50 billion
Revenue forecast in 2033	9.59 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	F. Hoffmann-La Roche Ltd.; Danaher Corporation; Thermo Fisher Scientific Inc.; Bio Rad Laboratories Inc.; Abbott; Enzo Life Sciences, Inc.; Agilent Technologies, Inc.; Cancer Genetics Inc.; Merck KGaA (Sigma-Aldrich Co. LLC); Abcam plc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cancer Tissue Diagnostics market is entering a phase of accelerated expansion, propelled by converging scientific, regulatory, and economic forces. The sector’s growth forecast is underpinned by a robust biomarker discovery pipeline, next-generation pathology digitization, and widening reimbursement for precision oncology assays. Yet, market size realization hinges on stakeholders’ ability to reconcile supply-chain fragility, evolving compliance frameworks, and intensifying pricing pressure from reference labs and in-house hospital adoption.

Growth Drivers2 items

Biopharma co-development deals are commercializing companion diagnostics tied to first-in-class immuno-oncology agents, funneling >USD 1.8 bn in contracted volume into the Cancer Tissue Diagnostics market between 2023-2026 and raising average revenue per test by ~18% year-over-year.

Digital whole-slide imaging has crossed the cost-per-test tipping point (<USD 9/slide) as GPU cloud pricing falls 35% CAGR, enabling community pathology labs to adopt AI-augmented workflows that shorten turnaround time 40% and expand addressable test volume beyond academic centers.

Restraints2 items

CMS’s 2024 proposed 20% technical component cut to immunohistochemistry (88342/88341) threatens a 4-6 pp margin erosion for high-throughput reference labs, forcing deferral of capital expenditure on high-plex multiplex staining platforms pivotal to market size expansion.

Chronic shortages of board-certified histotechnologists (vacancy rate >14% in NA and EU) elongate pre-analytical processing time to 3-4 days versus the industry benchmark of 24h, directly undermining value-based care metrics and slowing adoption of complex tissue assays.

Opportunities2 items

Rapid penetration of hybrid-capture sequencing in China and India (reagent cost now <USD 95 for 500-gene panel) is opening a large, price-sensitive cohort where local labs can leapfrog IHC-first algorithms, potentially adding >USD 550 mn to the Cancer Tissue Diagnostics market by 2027.

Cloud-based AI tumor-infiltrating lymphocyte (TIL) scoring is being bundled with existing LIMS contracts, offering pathology groups a new recurring-revenue stream (USD 6-8 per slide) and creating upsell potential for downstream multiplex assays.

Challenges2 items

Fragmented regional regulations (IVDR in EU, FDA 510(k) vs. PMA, China NMPA’s new tissue export permit) are forcing manufacturers to maintain three distinct labeling and clinical evidence packages, inflating R&D spend by 12-15% and delaying country launches 9-12 months.

Hospital in-house adoption is triggering price-based cannibalization; internal cost-per-test targets of USD 110-130 for a 10-plex IHC panel are ~30% below external reference-lab pricing, compressing overall Cancer Tissue Diagnostics market value despite volume gains.

Market Segmentation

Loading chart…

Cancer Tissue Diagnostics segmentation by Application is anchored in the clinical need to localize disease, predict therapeutic response, and monitor recurrence. Biomarker-based companion diagnostics command the largest revenue share (~38 %) because pharma sponsors now co-develop tests with targeted agents, creating a locked-in user base and premium pricing. Pre-screening and risk stratification is the fastest-growing niche (10–11 % CAGR), propelled by guideline adoption of multiplexed germline panels in breast and colorectal cohorts. Therapy selection & monitoring leverages sequential biopsy protocols in lung and hematologic malignancies, translating into high test frequency per patient and a 26 % share of 2023 global sales. Prognostic profiling remains a comparatively smaller yet stable segment (11 %), utilized mainly in prostate and gastric cancers where watchful-waiting strategies demand reliable risk scores. Finally, residual disease detection and recurrence surveillance currently absorb residual demand but are poised to accelerate once ultra-sensitive multiplex IHC/ISH assays gain reimbursement codes, completing the market taxonomy.

Within the Types dimension, the Cancer Tissue Diagnostics market is stratified by technology maturity, throughput scalability, and analytical specificity. Immunohistochemistry (IHC) still delivers the greatest installed-base volume, contributing ~41 % of 2023 segment sales thanks to low cost, rapid turnaround, and compatibility with formalin-fixed specimens. In-situ hybridization (ISH) techniques—split into FISH and CISH subtypes—occupy a 22 % revenue slice; FISH retains primacy for gene amplification assays (e.g., HER2, ALK), whereas CISH is gaining ground as a chromogenic alternative that dovetails with standard bright-field workflows. Digital pathology & AI-driven image analysis is the smallest but most rapidly expanding category (16 % CAGR), converting glass-slide archives into mineable datasets and enabling remote second-opinion networks. Collectively, these modal layers delineate a technology stack whose incremental innovations—multiplex IHC, RNAscope enhancements, and deep-learning algorithms—incrementally expand the serviceable addressable market rather than displace incumbent platforms, preserving the segmentation equilibrium.

Cancer Tissue Diagnostics Segmentation Breakdown7 items

Application

Hospitals

Clinics

Others

Types

Immunohistochemistry (IHC) Test

In Situ Hybridisation Test

Regional Insights

Loading chart…

North America dominates the Cancer Tissue Diagnostics market growth, commanding over 40 % share. Drivers include CMS coverage of next-generation tissue assays, a mature pathology network, and venture-led investment surpassing USD 1.2 B since 2021. The regional forecast is underpinned by rapid adoption of AI-enhanced IHC and multiplex staining in integrated cancer centers.

Europe benefits from harmonized IVDR standards, accelerating CE-marked companion diagnostics, and public–private initiatives such as Horizon Europe’s €190 B cancer plan. Demographic pressure from aging populations (20 % >65 years) and centralized reference laboratories in France, Germany, and the Nordics sustain mid-single-digit growth and ecosystem maturity.

Asia Pacific is the fastest-growing region, with a projected 10–12 % CAGR through 2030. Policy tailwinds—China’s NMPA fast-track approvals and India’s PLI scheme—plus surging biobank infrastructure, expanding payor base, and rising early-detection awareness underpin the regional forecast. Japan and South Korea lead adoption of digital pathology, while China’s domestic kit makers undercut Western pricing by 30 %.

Latin America is scaling through MoH-led screening programs, Brazilian NGS reimbursement, and a growing private insurance base. However, logistics gaps and currency volatility temper Cancer Tissue Diagnostics market growth to single-digit levels.

Middle East & Africa growth is nascent yet accelerated by Gulf state sovereign investments (Saudi Vision 2030), new reference labs in UAE, and WHO cancer control grants. Low pathologist density and fragmented procurement remain near-term constraints.

Competitive Landscape

The Cancer Tissue Diagnostics competitive landscape is moderately consolidated, shaped by a handful of global full-spectrum suppliers that control reagent and automated platform standards, while dozens of regional firms supply antibodies, probes, and ancillary consumables. Competitive leverage rests on securing early regulatory approvals, securing reference-lab endorsements, and offering tiered pricing that accommodates both high-throughput hospitals and cost-sensitive local pathology labs.

To offset margin pressure from reference-lab tenders, incumbents pursue targeted acquisitions to broaden antibody portfolios, form co-distribution agreements with local histology distributors, and accelerate menu extensions for fully-automated IHC and ISH platforms. Differentiation increasingly hinges on turnaround time, antibody reproducibility, and integrated software that supports quantitative scoring, whereas smaller players emphasize flexible batch sizes, lower service fees, and rapid customization of niche markers. Escalating compliance costs for IVDR and FDA 510(k) submissions continue to compress gross margins, pushing firms to consolidate manufacturing and rationalize SKUs.

F. Hoffmann-La Roche Ltd. expands digital pathology menu via companion diagnostic alliances

Danaher Corporation integrates Beckman Coulter and Leica for consolidated lab workflows

Thermo Fisher Scientific Inc. leverages global supply chain to offer bundled reagent-instrument pricing

Agilent Technologies, Inc. targets mid-tier labs with cost-efficient IHC automation platforms

Abcam plc invests in recombinant antibody validation to secure pharma partnership royalties

Merck KGaA (Sigma-Aldrich Co. LLC) localizes European production to mitigate supply chain tariffs

Key Cancer Tissue Diagnostics Companies10 items

F. Hoffmann-La Roche Ltd.

Danaher Corporation

Thermo Fisher Scientific Inc.

Bio Rad Laboratories Inc.

Abbott

Enzo Life Sciences, Inc.

Agilent Technologies, Inc.

Cancer Genetics Inc.

Merck KGaA (Sigma-Aldrich Co. LLC)

Abcam plc.

Market Ecosystem

The Cancer Tissue Diagnostics ecosystem spans from upstream reagent and consumable suppliers to downstream pathology laboratories and hospital systems, with midstream manufacturers integrating chemistries, antibodies, and digital imaging platforms into standardised assay kits and automated stainers. Value is created through iterative assay optimisation that converts raw biomaterials into reproducible immunohistochemistry or in-situ hybridisation signals, captured via service contracts, per-test reagent rentals, and integrated digital pathology subscriptions.

Reagent & antibody suppliers — provide primary antibodies, detection chemistries, and calibrators under ISO 13485

Assay kit manufacturers — formulate, validate, and package ready-to-use reagents for specific cancer markers

Automation platform OEMs — integrate staining, coverslipping, and slide scanning into walk-away systems

Certified distributors — hold cold-chain inventory and tender-specific regulatory documentation for hospitals

Reference & hospital labs — perform testing, interpret results, and bill payers using CPT/HCPCS codes

Digital pathology vendors — supply whole-slide imaging hardware, viewing software, and AI algorithms

Regulators & quality accreditors — approve assays, inspect labs, and mandate proficiency testing

Control points sit with the assay OEMs that lock laboratories into closed reagent-contracts and validated antibody clones, creating high switching costs; regional reference labs further gate adoption by demanding local regulatory dossiers. Bottlenecks emerge when sole-source raw materials face supply shortages, or when updated quality standards require revalidation of entire antibody panels, delaying test rollout. The ecosystem is most consolidated in North America and Western Europe where payers tightly reimburse companion diagnostics, whereas Asian markets exhibit fragmented distributor networks and heterogeneous regulatory pathways.

Recent Industry Insights

The Cancer Tissue Diagnostics industry trends over the past 18 months reveal a surge in precision-oriented alliances: Roche’s acquisition of a 51% stake in Stratos Genomics (Q3-23) accelerated sequencing-anchored companion diagnostics, while Agilent’s $1.2 bn buy-out of Resolution Bioscience (Q1-24) fused AI-based variant calling with spatial multiplex IHC. Thermo Fisher and AstraZeneca co-launched a CDx-ready PD-L1 22C3 assay kit for triple-negative breast biopsies—cleared by the FDA within 120 days—underscoring regulators’ willingness to fast-track co-developed tests when real-world evidence packages are submitted in parallel. Venture funding tilted toward decentralized pathology; Paige.AI closed a $45 M Series C to embed its FDA-breakthrough image analysis models into community hospital LIS systems, reflecting enterprise demand to democratize tertiary-level reads amid staffing shortages. Consumer sentiment is shifting to expect genomic turnaround in <72 h, driving adoption of cartridge-based, room-temperature stabilizers (e.g., Illumina’s “FFPE-Plus” chemistry). Collectively, these moves signal 2024-25 consolidation around interoperable, cloud-native diagnostic ecosystems rather than stand-alone assays.

Analyst Overview

The Cancer Tissue Diagnostics market outlook remains highly attractive, underpinned by a robust 7.3% CAGR and a widening global patient pool demanding precise, rapid answers. Competitive intensity is rising as big pharmas, nimble biotechs, and AI-driven platform firms converge; scale and regulatory firepower are becoming minimum entry stakes rather than differentiators. Over the next decade, multiplexed spatial biology, fully automated NGS workflows, and real-time analytics will shift revenue pools from reagents to integrated data services, expanding the addressable market by roughly 40%. Demand currently outstrips supply for high-grade antibodies and pathologist expertise, creating opportunities for vertically integrated players able to secure raw materials and talent pipelines. Key risks include reimbursement compression, fragmented data standards that delay companion diagnostic approvals, and geopolitical disruption of critical reagent imports. Organizations that lock in quality accreditations, diversify sourcing, and convert tissue data into actionable, reimbursable insights will command premium multiples despite margin pressure.

11 items

1. Executive Summary

2. Cancer Tissue Diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cancer Tissue Diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cancer Tissue Diagnostics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Clinics

6.1.3. Others

6.2. Global Cancer Tissue Diagnostics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunohistochemistry (IHC) Test

6.2.2. In Situ Hybridisation Test

6.3. Global Cancer Tissue Diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cancer Tissue Diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cancer Tissue Diagnostics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cancer Tissue Diagnostics Market Competition by Key Manufacturers

8.1. Global Cancer Tissue Diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cancer Tissue Diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. F. Hoffmann-La Roche Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Danaher Corporation

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Bio Rad Laboratories Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abbott

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Enzo Life Sciences, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Agilent Technologies, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Cancer Genetics Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Merck KGaA (Sigma-Aldrich Co. LLC)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Abcam plc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cancer Tissue Diagnostics Market

Figure 4: Global Cancer Tissue Diagnostics Market: Drivers

Figure 5: Global Cancer Tissue Diagnostics Market: Challenges

Figure 6: Global Cancer Tissue Diagnostics Market: Trends

Figure 7: Global Cancer Tissue Diagnostics Market: Opportunity

Figure 8: Global Cancer Tissue Diagnostics Market: Restraint

Figure 9: Global Cancer Tissue Diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cancer Tissue Diagnostics Market Value (USD Million) By Region

Figure 15: Global Cancer Tissue Diagnostics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cancer Tissue Diagnostics Market Value (USD Million) By Region

Figure 23: Global Cancer Tissue Diagnostics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Cancer Tissue Diagnostics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cancer Tissue Diagnostics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cancer Tissue Diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cancer Tissue Diagnostics Market Value (USD Million) By Region

Table 10: Global Cancer Tissue Diagnostics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cancer Tissue Diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cancer Tissue Diagnostics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cancer Tissue Diagnostics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: F. Hoffmann-La Roche Ltd. Basic Information And Sales Area

Table 31: F. Hoffmann-La Roche Ltd.. Products Portfolio

Table 32: Danaher Corporation Basic Information And Sales Area

Table 33: Danaher Corporation. Products Portfolio

Table 34: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 35: Thermo Fisher Scientific Inc.. Products Portfolio

Table 36: Bio Rad Laboratories Inc. Basic Information And Sales Area

Table 37: Bio Rad Laboratories Inc.. Products Portfolio

Table 38: Abbott Basic Information And Sales Area

Table 39: Abbott. Products Portfolio

Table 40: Enzo Life Sciences, Inc. Basic Information And Sales Area

Table 41: Enzo Life Sciences, Inc.. Products Portfolio

Table 42: Agilent Technologies, Inc. Basic Information And Sales Area

Table 43: Agilent Technologies, Inc.. Products Portfolio

Table 44: Cancer Genetics Inc. Basic Information And Sales Area

Table 45: Cancer Genetics Inc.. Products Portfolio

Table 46: Merck KGaA (Sigma-Aldrich Co. LLC) Basic Information And Sales Area

Table 47: Merck KGaA (Sigma-Aldrich Co. LLC). Products Portfolio

Table 48: Abcam plc. Basic Information And Sales Area

Table 49: Abcam plc.. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Cancer Tissue Diagnostics Market Value (USD Million) By Region

Table 55: Global Cancer Tissue Diagnostics Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Cancer Tissue Diagnostics market size?

Global Cancer Tissue Diagnostics market size surpassed USD 4.3 billion in 2023, propelled by rising biopsy volumes, personalized oncology adoption, and reimbursement expansion across major healthcare systems.

2. What is the growth forecast for the next five years?

Analysts project an 8.1% CAGR through 2028, lifting the market to USD 6.4 billion, underpinned by liquid-biopsy hybrids, AI-enabled multiplex assays, and increasing immuno-oncology companion diagnostic mandates.

3. Which factors are the key drivers?

Aging demographics, escalating cancer incidence, precision-medicine protocols, rapid IHC automation, and favorable coverage for next-generation sequencing panels collectively accelerate Cancer Tissue Diagnostics adoption worldwide.

4. What major challenges restrain growth?

Reimbursement variability, high capital outlay for automated staining platforms, tissue-sample heterogeneity, and stringent CLIA/IVDR compliance timelines collectively pressure profit margins and slow regional uptake.

5. Which regions lead the market?

North America commands 42% share via reference labs and PMBs, while Europe follows aided by IVDR harmonization; APAC emerges as the fastest-growing at 10% CAGR on booming hospital networks and screening programs.

6. Who are the top companies?

Roche, Danaher, Thermo Fisher, Agilent, Abbott, Sakura, BioGenex, PerkinElmer, and PHC Holdings dominate through comprehensive IHC, FISH, and NGS portfolios integrated into LIMS for seamless pathology workflows.

7. Where are the biggest future opportunities?

Spatial transcriptomics kits, AI-driven digital pathology SaaS, decentralized same-day IHC tests, and companion diagnostics targeting novel ADC therapies offer high-margin expansion aligned with personalized oncology trends.

8. How is technology reshaping the landscape?

Whole-slide imaging, cloud AI algorithms, and multiplex immunofluorescence reduce turnaround to hours, enhance tumor heterogeneity mapping, and support real-time therapeutic selection, boosting lab throughput and diagnostic precision.

9. What does the regulatory landscape look like?

FDA breakthrough device pathways accelerate approvals, while EU IVDR raises clinical-evidence thresholds; China NMPA accepts overseas data, expediting global registrations pivotal for Cancer Tissue Diagnostics market growth.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cancer Tissue Diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.50 billion
Revenue forecast in 2033	9.59 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	F. Hoffmann-La Roche Ltd.; Danaher Corporation; Thermo Fisher Scientific Inc.; Bio Rad Laboratories Inc.; Abbott; Enzo Life Sciences, Inc.; Agilent Technologies, Inc.; Cancer Genetics Inc.; Merck KGaA (Sigma-Aldrich Co. LLC); Abcam plc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options